A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects

Exclusion Criteria

• •Ongoing or history of any medical or surgical condition that, in the judgment of the Investigator, might jeopardize the subject's safety or interfere with the study objectives
• •History of meningitis or encephalitis, seizures, migraines, tremors, myoclonic jerks, sleep disorder, anxiety, syncope, head injuries or a family history of seizures
• •Any abnormal ECG findings, abnormal laboratory value, or physical examination findings at Screening judged to be clinically significant
• •Any abnormal neurological examination findings at Screening that is judged as clinically significant
• •Hemoglobin \< 12 g/dL
• •Serology test positive for HIV, or hepatitis B or C
• •Positive urine drug test (including cotinine or ethanol)
• •Use of systemic prescription medications or over the counter (OTC) medication, including multivitamins, and dietary and herbal supplement
• •Use of any experimental or investigational drug or device within 30 days
• •Female subjects who are of childbearing potential, pregnant or lactating
• •Donation or loss of blood within 8 weeks and/or donation of plasma within 7 days
• •History of drug or alcohol abuse
• •Psychosocial or addictive disorders